{"url":"https://newsforagent.com/news/2026-10-25/oruka-therapeutics-orka-001-week-16-data","markdown_url":"https://newsforagent.com/news/2026-10-25/oruka-therapeutics-orka-001-week-16-data.md","title":"Oruka Therapeutics to Report ORKA-001 Week 16 Data","headline":"Oruka Therapeutics Sets October 26 Call for ORKA-001 Week 16 Data From EVERLAST-B","description":"Oruka Therapeutics will report Week 16 data for ORKA-001 from the Phase 2b EVERLAST-B trial on October 26, 2026, followed by an 8:00 a.m.","section":"Research & Clinical Trials","published_at":"2026-10-25T16:21:40+00:00","modified_at":"2026-10-25T16:21:40+00:00","author":"News Desk","key_takeaways":["Oruka Therapeutics will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial on October 26, 2026.","The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.","Oruka Therapeutics is a clinical-stage biotechnology company developing biologics for plaque psoriasis and hidradenitis suppurativa."],"companies":[{"name":"Oruka Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000yz/oruka-therapeutics","website":"https://www.orukatx.com"}],"source":{"publisher":"Stock Titan","title":"Oruka to report ORKA-001 Week 16 data Oct. 26","url":"https://www.stocktitan.net/news/ORKA/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-r6izbdom8sjh.html"},"other_sources":[],"tags":["Research & Clinical Trials","Oruka Therapeutics"],"body_markdown":"Oruka Therapeutics will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on October 26, 2026, according to [Stock Titan](https://www.stocktitan.net/news/ORKA/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-r6izbdom8sjh.html). The company will host a conference call and webcast at 8:00 a.m. ET that day to discuss the results.\n\n## Oruka Therapeutics Sets EVERLAST-B Data Call\n\n[Oruka Therapeutics](https://akta.pro/company-profiles/00000yz/oruka-therapeutics) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases including plaque psoriasis and hidradenitis suppurativa. The company said the Week 16 data will come from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis.\n\nOruka Therapeutics said the live webcast of the EVERLAST-B results will begin on October 26 at 8:00 a.m. ET. The company said the webcast can be accessed through the Investors section of its [website](https://www.orukatx.com), and that a replay will be available following the call.\n\n## Oruka Therapeutics' Funding and Partnerships\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Oruka Therapeutics priced an upsized underwritten public offering of approximately $700.4 million at $72.50 per share in April 2026, the largest single capital raise in company history and the primary source of the roughly $857 million cash position reported at the end of the first quarter of 2026. The same records show the company entered a global exclusive collaboration and license agreement with Halozyme Hypercon in May 2026 covering ORKA-001 and up to one additional target, with mid-single digit royalties owed to Halozyme in exchange for extended half-life engineering. In June 2026, Oruka Therapeutics amended its IL-23 License Agreement with Paragon Therapeutics to broaden licensed uses of the IL-23 pipeline assets to therapeutic, prophylactic, palliative, and diagnostic applications.\n\n## Earlier Oruka Therapeutics Trial Results\n\nOruka Therapeutics reported Week 28 data from EVERLAST-A showing 71.4% PASI 100 and 87.3% PASI 90 with only two doses, Seeking Alpha reported on October 18, 2026. The crossover arm matched the active arm's response, and Phase 3 trials are planned for 2027, according to the same report.\n\nOruka Therapeutics appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026, drawing him from Arcutis Biotherapeutics where he led the ZORYVE franchise, Investing.com reported on August 24, 2026.\n\n## Oruka Therapeutics' Next Steps\n\nOruka Therapeutics said the conference call and webcast to discuss the EVERLAST-B Week 16 results will take place on October 26, 2026 at 8:00 a.m. ET. The company said a replay of the webcast will be available following the call.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}